Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients
DOI:
https://doi.org/10.23938/ASSN.1056Keywords:
Antiviral Agents, Drug Interactions, COVID-19 Drug Treatment, Patient Safety, Primary Health CareAbstract
Background. The oral antiviral nirmatrelvir/ritonavir interacts with a range of drugs. Candidate patients are usually vulnerable, multipathological and polymedicated. The objective is to evaluate the pharmaceutical validation prior to the administration of the antiviral.
Material and methods. Drug-drug interactions between nirmatrelvir/ritonavir and patients' usual treatment medications were checked in product information and in the UpToDate® and the University of Liverpool® interaction tools. We included validated prescriptions between April/2022 and April/2023 by a Primary Care pharmacist.
Results. Of the 159 study patients, 168 interactions were found in 83 individuals, which may have led to changes of their usual treatment. Statins (25.6%), anticoagulants (10.7%), and antihypertensives (10.7%) were the most frequently implicated therapeutic groups. Discontinuation (53.0%) and dose reduction (22.6%) were the most common treatment changes.
Conclusions. Our search of potential drug interactions and subsequent dose adjustments and modifications of the patient's usual treatment has helped avoid potential toxicities ensuring a safe use of nirmatrelvir/ritonavir.
Downloads
References
Centro de información online de medicamentos de la Agencia Española de Medicamentos y Productos Sanitarios. Buscador para profesionales sanitarios. https://cima.aemps.es/cima/publico/buscadoravanzado.html
Agencia Española de Medicamentos y Productos Sanitarios. Criterios para valorar la administración de las nuevas alternativas terapéuticas antivirales frente a la infección por SARS-CoV-2. Version 7. Consultada el 8 de febrero de 2023. https://www.aemps.gob.es/medicamentos-de-uso-humano/acceso-a-medicamentos-en-situaciones-especiales/criterios-para-valorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-antivirales-frente-a-la-infeccion-por-sars-cov-2/
VUORIO A, RAAL F, KOVANEN PT. Drug-drug interaction with oral antivirals for the early treatment of COVID-19. Int J Infect Dis 2023;127:171-172. https://doi.org/10.1016/j.ijid.2022.11.039
ABRAHAM S, NOHRIA A, NEILAN TG, ASNANI A, SAJI AM, SHAH J et al. Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19. J Am Coll Cardiol 2022; 80(20): 1912-1924. https://doi.org/10.1016/j.jacc.2022.08.800
LEMAITRE F, GRÉGOIRE M, MONCHAUD C, BOUCHET S, SAINT-SALVI B, POLARD E et al. Management of drug-drug interactions with nirmatrelvir / ritonavir in patients treated for Covid-19 : Guidelines from the French (SFPT). Therapies 2022: 509-521. https://doi.org/10.1016/j.therap.2022.03.005
Lexicomp Drug Interactions. Consultado el 3 de julio de 2023. https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist
Liverpool University. COVID-19 Drug Interactions. Accessed July 3, 2023. https://www.covid19-druginteractions.org/
GUY-ALFANDARY S, ZHURAT S, BERLIN M, HAAN TD, GUETA I, SHIHMANTER R. Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration. Clin Pharmacol Ther 2022;112(6):1156-1158. https://doi.org/10.1002/cpt.2610
MARZOLINI C, KURITZKES DR, MARRA F, BOYLE A, GIBBONS S, FLEXNER C Et al. Recommendations for the Management of Drug–Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther 2022;112(6):1191-1200. https://doi.org/10.1002/cpt.2646
ROSS SB, BORTOLUSSI-COURVAL É, HANULA R, LEE TC, GoODWIN WILSON M, MCDONALD EG. Drug Interactions with Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications. JAMA Netw Open 2022; 5(7): E2220184. https://doi.org/10.1001/jamanetworkopen.2022.20184
LARSEN CS. Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. Int J Infect Dis 2022;122: 599-601. https://doi.org/10.1016/j.ijid.2022.06.059
KANE AM, KEENAN EM, LEE K, HARTKOPF K, LUDWING TA, TRAPSKIN P et al. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study. JACCP J Am Coll Clin Pharm 2023; 6(1): 29-33. https://doi.org/10.1002/jac5.1729
VAZQUEZ SR, WILSON AS, WITT DM. Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series. J Thromb Thrombolysis 2022; 54(4): 583-586. https://doi.org/10.1007/s11239-022-02707-4
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
